Related Experiment Videos
Living-donor liver transplantation for propionic acidaemia
T Yorifuji1, M Kawai, M Mamada
1Department of Pediatrics, Kyoto University Hospital, 54 Shogoin Sakyo, Kyoto 606-8507, Japan. yorif@kuhp.kyoto-u.ac.jp
Journal of Inherited Metabolic Disease
|May 26, 2004
Summary
Living-donor liver transplantation (LDLT) significantly reduces metabolic decompensation in severe propionic acidemia patients. While quality of life improves, continued protein restriction and medication are crucial post-transplant.
Area of Science:
- Biochemistry
- Transplantation Medicine
- Metabolic Disorders
Background:
- Propionic acidemia is a severe metabolic disorder.
- Living-donor liver transplantation (LDLT) is a potential treatment for severe cases.
Observation:
- Three patients with severe propionic acidemia underwent LDLT.
- All transplantations were successful, leading to reduced metabolic decompensation.
- Patients experienced improved quality of life with less dietary protein restriction.
Findings:
- Biochemical improvements were not significant, with continued excretion of propionic acid metabolites.
- One patient had a severe acidaemic episode three years post-transplant.
- LDLT reduces metabolic decompensation risk and improves quality of life.
Implications:
- LDLT offers significant benefits for managing severe propionic acidemia.
- Continued protein restriction and medication are essential even after successful LDLT.
- Long-term biochemical monitoring is necessary to manage residual metabolic defects.